The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Epidemiology and Prevention
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1481242
COVID -19 pandemic shift epidemiology for cancer sites screening: breast, cervical, colon, rectum
Provisionally accepted- 1 Department of Radiation Therapy, Almaty Oncology Center, Almaty, Kazakhstan
- 2 Chairman of the Board of the Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
- 3 Oncology Department Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
- 4 Public health expert, Club of Experts under the Senate of Republic of Kazakhstan, Astana, Kazakhstan
- 5 Member of the Board, Kazakhstan Association of Healthcare Managers, Astana, Kazakhstan
- 6 Department of screening Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
- 7 Centre for Molecular Genetic Research Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
- 8 Department of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan
- 9 Department of Mammology Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
This study aimed to assess the epidemiological changes for breast, cervical colon and rectum cancer in Kazakhstan before and during the COVID-19 by using data of Oncological service of the Republic of Kazakhstan for 2017 -2022 period of years.The cohort comprised of patients aged 20 to 49 years -EOC and aged 50 years and olderlate-onset cancer (LOC) from the total number of patients diagnosed each year during the study period from 2017 to 2022 for breast, cervical, сolon and rectum cancer type. In order to indicate a difference in one-time interval and to characterize the global trend over the entire study period Annual percentage change (APC) and average APC (AAPC) were calculated, correspondingly.Results: Breast cancer detection rates increased by 22.8% for EOC and 15.9% for LOC from 2017 to 2022, AAPC increased by 4.3% for EOC and 3.6% for LOC. During the COVID-19 restriction period, breast cancer detection rates decreased by 6.1% for EOC and 15.6% for LOC. Cervical cancer detection rates increased by 2.3% for EOC and 7.5% for LOC from 2017 to 2022, AAPC increased by 0.9% for EOC and 1.6% for LOC. During the COVID-19 restriction period, cervical cancer detection rates decreased by 11.3% for EOC and 3.1% for LOC. Colon cancer detection rates increased by 18.4% for EOC and 14.3% for LOC from 2017 to 2022, AAPC increased by 3.7% for EOC and 2.9% for LOC. During the COVID-19 restriction period, colon cancer detection rates decreased by 14.4% for EOC and 5.8% for LOC. Rectum cancer detection rates increased by 13.6% for EOC and 19.2% for LOC from 2017 to 2022, AAPC increased by 3.0% for EOC and by 3.9% for LOC. During the COVID-19 restriction period, rectum cancer detection rates increased by 18.6% for EOC and decreased by 12.0% for LOC.The epidemiological indicators of population cancer screening have worsened during the COVID pandemic, the detection rate for breast cancer EOC decreased by 6.1%, for cervical cancer EOC decreased by 11.3%, while there was an increase in EOC for colon cancer in men by 38.0%, and rectum cancer in men by 8.0%, and women by 31.1%.
Keywords: cancer screening, breast cancer, cervical cancer, Colon Cancer, Rectum cancer, COVID-19, early-onset cancer
Received: 15 Aug 2024; Accepted: 26 Dec 2024.
Copyright: © 2024 Ishkinin, Kaidarova, Aidossov, Zhylkaidarova, Ossikbayeva, Mussina and Omarbayeva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Serzhan Aidossov, Public health expert, Club of Experts under the Senate of Republic of Kazakhstan, Astana, Kazakhstan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.